Pharma Industry News: 29 September 2025

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

FDA Voucher Ignites IRON Stock Rally Disc Medicine’s stock price (NASDAQ: IRON) spiked dramatically in mid-October 2025 after news of the FDA voucher, vaulting from the mid-$70s to the low-$90s in a

17 October 2025

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases investor.omeros.com. Under

15 October 2025

Financial Analysis · Investment News · Mergers & Acquisitions · Pharma Industry · Stock Market

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The

15 October 2025

Artificial Intelligence · Biotechnology · Investment Trends · Pharma Industry · Stock Market

Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?

Latest News & Developments On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55

14 October 2025

Financial News · Investing · Mergers & Acquisitions · Pharma Industry · Stock Market

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease newamsterdampharma.com.

11 October 2025

Biotech Innovations · Health Stocks · Investment Tips · Pharma Industry · Stock Market News

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech fiercebiotech.com; MarketBeat and DirectorsTalk analyst surveys marketbeat.com directorstalkinterviews.com; Economic Times deal summary economictimes.indiatimes.com economictimes.indiatimes.com; Business Wire legal alert businesswire.com businesswire.com; and TradingView market data marketbeat.com tradingview.com.

9 October 2025

Biotech News · Investment Insights · Mergers & Acquisitions · Pharma Industry · Stock Market

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

Latest News (Oct 7–Oct 9, 2025) Stock Performance & Technical Analysis After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had

9 October 2025

Artificial Intelligence · Biotechnology · Drug Discovery · Pharma Industry · Stock Market

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Stock Performance: From Laggard to Late-September Lift For much of 2025, Pfizer’s stock was stuck in a rut – but that changed dramatically as Q4 approached. By late September, PFE had drifted

6 October 2025

Business News · Healthcare · Investment Trends · Pharma Industry · Stock Market

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

In‑Depth Report Introduction Eli Lilly and Company (NYSE: LLY) has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro (for type 2 diabetes) and Zepbound (for

6 October 2025

Biotech News · GLP‑1 Drugs · Investment Analysis · Pharma Industry · Stock Market

Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Sources: Company filings and press releases globenewswire.com stocktitan.net; financial media (Reuters, Investing.com, Stocktwits, Seeking Alpha) reuters.com stocktwits.com investing.com; market data services stocktitan.net tipranks.com. All figures and quotes are from cited reports.

29 September 2025

Biotech Stocks · Clinical Trials · Investment Risks · Pharma Industry · Stock Analysis · Stock Market

Pharma Industry News: 29 September 2025 - 17 October 2025